Evidence Strategy & Market Access Consulting for
Biotech and MedTech.
Evidence-in-Action™ helps Biotech and MedTech innovators translate the right evidence into the right decisions – faster- so you can de-risk development, strengthen market access, and improve patient impact.
From Evidence Strategy to Stakeholder Action: Payer Readiness for Biotech and MedTech
MedNavigate enables early to mid-size biotech and med tech teams align evidence strategy with payer expectations, stakeholder needs, and commercial reality.
-
Strategic Evidence
-
Payer Insights
-
Market Access Clarity
Where Clinical Evidence Meets Payer Access Strategy
Strong science does not automatically translate into payer coverage, provider adoption, or commercial success. That’s why we developed a series of Evidence-in-Action(TM) service offering to equip your teams with the knowledge and the evidence plan to fuel success in today’s complex healthcare marketplace.
MedNavigate’s Evidence-in-Action portfolio brings together focused advisory offerings that help organizations assess payer readiness, shape evidence strategy, translate complex findings into stakeholder-ready communication, and add senior value-and-access leadership when needed. Each engagement is designed to address a different access challenge, while keeping evidence aligned with the decisions that matter most. Ultimately, we help our clients to bridge the gap between clinical evidence, payer expectations, and stakeholder action, so important decisions are supported by a strategy that is credible, aligned, and ready to work in the real world.
From Evidence Strategy to Stakeholder Action: Payer Readiness for Biotech and MedTech
MedNavigate enables early to mid-size biotech and med tech teams align evidence strategy with payer expectations, stakeholder needs, and commercial reality.
- Strategic Evidence
- Payer Insights
- Market Access Clarity
Where Clinical Evidence Meets Payer Access Strategy
Strong science does not automatically translate into payer coverage, provider adoption, or commercial success. That's why we developed a series of Evidence-in-Action(TM) service offering to equip your teams with the knowledge and the evidence plan to fuel success in today's complex healthcare marketplace.
The Evidence-in-Action Portfolio
MedNavigate’s Evidence-in-Action portfolio brings together focused advisory offerings that help organizations assess payer readiness, shape evidence strategy, translate complex findings into stakeholder-ready communication, and add senior value-and-access leadership when needed. Each engagement is designed to address a different access challenge, while keeping evidence aligned with the decisions that matter most.
Evidence Snapshot
Low-priced structured introductory conversation to assess your current evidence landscape and payer readiness. Ideal for early-stage biotech and MedTech teams who need a fast, expert read on their biggest evidence gaps before committing to a full strategy engagement.
Evidence Accelerator
Early insight into payer-readiness gaps, evidence risk, and strategic next steps for medical device and biotech innovators. This engagement helps your team identify where your current data falls short of payer expectations and what actions will have the greatest commercial impact.
Evidence Architect
Strategic guidance to ensure evidence programs are built with clear purpose, audience relevance, and business value. Designed for organizations building or rebuilding their health economics and outcomes research (HEOR) strategy ahead of a product launch or major market access milestone.
Evidence Communicator
High-value support for turning complex clinical and economic findings into clear narratives for the payers, providers, and health system stakeholders who shape adoption. Ensures your evidence story is compelling, credible, and aligned with what decision-makers need to say YES.
Fractional Head of Value and Access:
Senior strategic leadership for organizations that need payer and access expertise without a full-time executive hire.